Novel treatment approaches of SLE have recently been reviewed, and while Belimumab is approved, Atacicept, a combined BAFF/APRIL inhibitor [55], is being further studied in phase II/III clinical trials [56]. Here, TNFSF13 is linked to systemic lupus erythematosus.